More than 25 million Americans live with a rare disease. While scientific advances have improved our ability to diagnose them, and cell and gene therapies offer promise to those afflicted with them, the rare disease community faces unique challenges in accessing appropriate care—from the "diagnostic odyssey" to obtaining insurance coverage. What are the current strategies for advancing access to rare disease therapies? How have these strategies fared? Where are the greatest opportunities to coordinate efforts and resources?